Related Experiment Video
Updated: Jun 18, 2026
13:34
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
[Effect of metabolizable peptide p16INK4a on short-lived human tumor cultures]
Voprosy Onkologii
|December 2, 2009
Abstract:
The study was concerned with antitumor action of internalized peptide incorporating a fragment of p161INK4a using a model of short-lived human tumor cultures sampled from resected material. Renal cancer sample showed the greatest therapeutic interval.
Insights
This study explored the antitumor effects of an internalized peptide derived from p161INK4a in human tumor cultures. Renal cancer models demonstrated the most promising therapeutic window for this peptide.
Area of Science:
- Oncology
- Molecular Biology
- Peptide Therapeutics
Context:
- Utilizing short-lived human tumor cultures derived from resected tissues.
- Investigating the cellular uptake and mechanism of action of a novel peptide.
- Focusing on the potential of peptide-based therapies in cancer treatment.
Purpose:
- To evaluate the antitumor efficacy of an internalized peptide containing a p161INK4a fragment.
- To determine the therapeutic interval of the peptide in various human tumor models.
- To identify specific cancer types that are most responsive to this peptide therapy.
Summary:
- The study assessed the antitumor activity of a peptide incorporating a p161INK4a fragment after cellular internalization.
- Experiments were conducted using patient-derived, short-lived human tumor cultures.
- The peptide demonstrated a significant therapeutic interval in renal cancer samples, indicating potential efficacy.
Impact:
- Identifies renal cancer as a promising candidate for p161INK4a-fragment peptide therapy.
- Provides a foundation for further preclinical and clinical development of targeted peptide treatments.
- Highlights the potential of internalized peptides in overcoming drug resistance mechanisms in cancer.
